FMI Releases New Report on the Substance Use Disorder Treatment Market 2017-2027

According to World Health Organization (WHO), the leading cause of disability around the world is not a physical disease, but a serious mood disorder known as depression. Around 350 million people suffer from depression worldwide, and that only about 50% of these individuals will ever receive treatment. According to Anxiety and Depression Association of America, in the U.S., over 15 million adults experience an episode of clinical depression in any given year, which is 7% of the population. Research has revealed that many of the factors that contribute to depression also play a part in substance use disorders. Substance use disorders lead to imbalances in brain chemistry, family history, and past trauma, for instance, are frequently involved in both depression and addiction. In addition, the physical and psychological effects of addiction may mask the signs of depression or worsen the symptoms of this psychiatric illness.

The increasing number of patients suffering from any addiction related to alcohol or tobacco, rising government initiatives and increasing support by NGOs and agenesis are the key factors which are propelling the substance use disorder treatment market. In regards of this, The Substance Abuse and Mental Health Services Administration (SAMHSA), a branch of the U.S Department of Health and Human Services has multiple programs to improve awareness. The SAMHSA organized various programs and initiatives with the help of government agencies and many organizations to increase awareness about the chronic ill-effects of substance abuse. Such programs are aimed to eradicate illicit drug use in federal workplaces and helps all workplaces become drug-free. However, the reluctance of individuals in accessing treatment modalities and the discontinuation of behavioral therapies leading to relapse are the factors which are restraining the growth of this market. Government initiatives and funding are key opportunities to this market.Substance Use Disorder Treatment Market Segmentation By Type – Alcohol Abuse Treatment, Nicotine Abuse Treatment, Drug Abuse Treatment; By Treatment – Detoxification, Counselling and Behavioral Therap, Medication, Support Group.

The global market for substance use disorder treatment is expected to witness moderate growth over the forecast period due to increasing initiatives by government and welfare agenesis initiatives. Furthermore, inclination of people towards less addiction of tobacco and alcohol, are the growth factor for the substance use disorder treatment market. However, breaking the substance abuse cycle is a difficult and tedious process. Hence, pharmaceutical manufacturers have developed several products to assist in recovery from substance abuse. The substance use disorder treatment is categorized by types which includes alcohol abuse treatment, nicotine abuse treatment, and drug abuse treatment. Out of that, alcohol abuse treatment segment expected to account the major share due to improved rehab facilities, increasing in government initiatives, and the rising awareness in developing countries.

Geographically, global substance use disorder treatment market is classified into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. North America and Europe together dominates the global substance use disorder treatment market due to increasing government initiatives and increasing prevalence of substance abuse in developed countries. Asia Pacific substance use disorder treatment market is expected to be one of the fastest growing markets due to large addicted population which requires firm treatments. The market for substance use disorder treatment is consolidated with a presence of few strong players. Some of the players identified in global substance use disorder treatment market include Teva Pharmaceutical Industries Ltd, Reckitt Benckiser Pharmaceuticals Inc., GlaxoSmithKline plc., Alkermes plc., Pfizer, Inc., Cipla Limited, Intas Biopharmaceuticals.

Request For Report Sample: